明心医药公司宣布扩大其治疗酒精使用障碍的创新药物CMND-100的I/IIa期临床试验规模，在约翰霍普金斯大学医学院新增临床研究中心，并已完成该站点首位受试者入组。这项突破性进展紧随耶鲁大学医学院前期受试者招募工作，标志着该口服候选药物研发进程的重要推进。
此次跨国多中心临床试验聚焦MEAI基创新化合物CMND-100的核心评估维度：药物安全性参数、人体耐受阈值及药代动力学特征。研究团队同步监测关键疗效指标，包括酒精渴求程度变化曲线与摄入量下降趋势等关键数据节点。现阶段试验核心目标在于确立最优给药方案，为后续酒精依赖症治疗领域的深度开发奠定科学基础。
需要特别说明的是，当前所有临床数据仍处于分析阶段，完整研究成果尚未正式披露。这项系统性研究通过多点协同推进的模式，将显著加速创新疗法的临床转化进程，为全球逾15亿酒精依赖患者群体带来新的治疗曙光。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.